A preclinical randomized controlled multi-centre trial of anti-interleukin-17A treatment for acute ischaemic stroke.
inflammation
interleukin-17A
preclinical randomized controlled trial
stroke
Journal
Brain communications
ISSN: 2632-1297
Titre abrégé: Brain Commun
Pays: England
ID NLM: 101755125
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
09
2022
revised:
19
01
2023
accepted:
22
03
2023
medline:
15
4
2023
entrez:
14
4
2023
pubmed:
15
4
2023
Statut:
epublish
Résumé
Multiple consensus statements have called for preclinical randomized controlled trials to improve translation in stroke research. We investigated the efficacy of an interleukin-17A neutralizing antibody in a multi-centre preclinical randomized controlled trial using a murine ischaemia reperfusion stroke model. Twelve-week-old male C57BL/6 mice were subjected to 45 min of transient middle cerebral artery occlusion in four centres. Mice were randomly assigned (1:1) to receive either an anti-interleukin-17A (500 µg) or isotype antibody (500 µg) intravenously 1 h after reperfusion. The primary endpoint was infarct volume measured by magnetic resonance imaging three days after transient middle cerebral artery occlusion. Secondary analysis included mortality, neurological score, neutrophil infiltration and the impact of the gut microbiome on treatment effects. Out of 136 mice, 109 mice were included in the analysis of the primary endpoint. Mixed model analysis revealed that interleukin-17A neutralization significantly reduced infarct sizes (anti-interleukin-17A: 61.77 ± 31.04 mm
Identifiants
pubmed: 37056478
doi: 10.1093/braincomms/fcad090
pii: fcad090
pmc: PMC10088471
doi:
Banques de données
figshare
['10.25452/figshare.plus.c.6371439']
Types de publication
Journal Article
Langues
eng
Pagination
fcad090Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.
Déclaration de conflit d'intérêts
The authors report no competing interests.
Références
Cancer Res. 2017 Nov 1;77(21):5706-5711
pubmed: 28993414
Nat Microbiol. 2021 Sep;6(9):1110-1117
pubmed: 34341528
J Autoimmun. 2019 Feb;97:29-39
pubmed: 30420263
Ann Neurol. 2006 Mar;59(3):467-77
pubmed: 16453316
Nature. 2012 Oct 11;490(7419):187-91
pubmed: 23060188
Nat Immunol. 2020 Nov;21(11):1421-1429
pubmed: 32929273
Front Neurosci. 2019 Aug 07;13:781
pubmed: 31440125
Nat Rev Genet. 2017 Nov;18(11):690-699
pubmed: 28824167
PLoS Biol. 2020 Jul 14;18(7):e3000411
pubmed: 32663221
Nat Biotechnol. 2019 Sep;37(9):1091
pubmed: 31399723
Int J Stroke. 2009 Dec;4(6):471-9
pubmed: 19930059
J Cereb Blood Flow Metab. 2012 Jun;32(6):933-5
pubmed: 22510602
Nat Biomed Eng. 2018 Nov;2(11):797-809
pubmed: 30931172
N Engl J Med. 2018 Aug 16;379(7):611-622
pubmed: 29766770
Elife. 2021 Dec 07;10:
pubmed: 34874008
Nature. 2014 Mar 27;507(7493):423-5
pubmed: 24678540
N Engl J Med. 2015 Jan 1;372(1):11-20
pubmed: 25517348
Nature. 2016 May 25;533(7604):452-4
pubmed: 27225100
Nat Immunol. 2017 May 18;18(6):612-621
pubmed: 28518156
Circ Res. 2020 Jul 31;127(4):453-465
pubmed: 32354259
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Front Aging Neurosci. 2020 Sep 04;12:274
pubmed: 33101005
Neurology. 2020 Aug 25;95(8):e1091-e1104
pubmed: 32591475
J Neurochem. 2016 Oct;139 Suppl 2:271-279
pubmed: 26968835
Stroke. 2018 Jan;49(1):155-164
pubmed: 29212740
Cell. 2021 Feb 18;184(4):1000-1016.e27
pubmed: 33508229
Acta Neuropathol. 2015 Feb;129(2):239-57
pubmed: 25548073
BMJ. 2010 Mar 23;340:c869
pubmed: 20332511
J Clin Invest. 2020 Jun 1;130(6):2777-2788
pubmed: 32391806
Sci Immunol. 2019 Oct 11;4(40):
pubmed: 31604844
Stroke. 2013 Jun;44(6):1754-60
pubmed: 23598526
N Engl J Med. 1995 Dec 14;333(24):1581-7
pubmed: 7477192
Elife. 2021 Dec 07;10:
pubmed: 34874005
Lancet Neurol. 2016 Jul;15(8):869-881
pubmed: 27180033
Stroke. 2019 Jun;50(6):1548-1557
pubmed: 31084324
Blood. 2012 Nov 1;120(18):3793-802
pubmed: 22976954
Neuron. 2021 Sep 1;109(17):2691-2706.e5
pubmed: 34473953
Circ Res. 2022 Apr 15;130(8):1167-1186
pubmed: 35420915
Front Neurol. 2019 Apr 24;10:397
pubmed: 31068891
EMBO Rep. 2019 Aug;20(8):e47379
pubmed: 31283095
Ann Neurol. 2020 Jan;87(1):40-51
pubmed: 31714631
Nat Immunol. 2019 Dec;20(12):1594-1602
pubmed: 31745337
Nat Med. 2016 May;22(5):516-23
pubmed: 27019327
Neuromolecular Med. 2022 Dec;24(4):437-451
pubmed: 35384588
Nat Rev Immunol. 2021 Aug;21(8):526-541
pubmed: 33649606
Elife. 2021 Jan 12;10:
pubmed: 33432925
Lancet Neurol. 2019 May;18(5):439-458
pubmed: 30871944
Stroke. 2009 May;40(5):1849-57
pubmed: 19265055
Sci Transl Med. 2015 Aug 5;7(299):299ra121
pubmed: 26246166
Nat Med. 2009 Aug;15(8):946-50
pubmed: 19648929
Cell. 2009 Oct 30;139(3):485-98
pubmed: 19836068
Stroke. 2004 Feb;35(2):566-71
pubmed: 14739415
Exp Neurol. 2012 Feb;233(2):597-605
pubmed: 22078756
J Anat. 1990 Jun;170:111-23
pubmed: 2254158
Acta Neuropathol. 2016 May;131(5):775-91
pubmed: 26860727
Stroke. 2014 May;45(5):1510-8
pubmed: 24652307
J Cereb Blood Flow Metab. 2016 Mar;36(3):596-605
pubmed: 26661169